GlassScriptPhysician profile
Rodney J Dean
NPI 1528037082
$10,763.87
in general payments reported to CMS, 2019-2025
35 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $1,135 · 2021: $1,561 · 2022: $1,035 · 2023: $1,714 · 2024: $2,238 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,847 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,846.56 |
| Education | $254.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,439.70 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,389.94 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $989.97 | 2021-2025 | Vraylar |
| Lundbeck LLC | $840.04 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $816.16 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $802.91 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $763.92 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $579.43 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $460.94 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $427.76 | 2021-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $358.96 | 2024-2025 | Cobenfy, Camzyos |
| Corium, LLC | $306.91 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $287.61 | 2019-2024 | Trintellix |
| Allergan, INC. | $177.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $170.83 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $156.44 | 2019 | |
| Axsome Therapeutics, INC. | $140.88 | 2024-2025 | Auvelity |
| Tris Pharma INC | $95.32 | 2020-2023 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $68.40 | 2020 | |
| Jazz Pharmaceuticals INC. | $54.95 | 2020-2021 | |
| Indivior INC. | $44.56 | 2021-2024 | Perseris |
| Acadia Pharmaceuticals INC | $43.78 | 2024 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $41.66 | 2022-2023 | Quviviq |
| Neuronetics, INC. | $41.50 | 2021-2025 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $34.56 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $31.41 | 2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $30.17 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $28.13 | 2020-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $25.17 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.01 | 2019 | |
| Adlon Therapeutics L.P. | $23.35 | 2020-2021 | |
| Bioxcel Therapeutics, INC. | $22.89 | 2024 | Igalmi |
| Almatica Pharma LLC | $15.95 | 2021 | |
| Bausch Health US, LLC | $14.67 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.